# EDGAR Filing Document

**Accession Number:** 0000856984
**File Stem:** 0001493152-23-005276
**Filing Date:** 2023-2
**Character Count:** 11753
**Document Hash:** d4ac7b9bbe63eaa78892798525abcac8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-005276.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001493152-23-005276

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230216

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QHSLab, Inc.
- **CENTRAL INDEX KEY:** 0000856984
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 112655906
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19041
- **FILM NUMBER:** 23637227

**BUSINESS ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407
- **BUSINESS PHONE:** (929) 379-6503

**MAIL ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITIES CORP.
- **DATE OF NAME CHANGE:** 20151119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITY CORP.
- **DATE OF NAME CHANGE:** 20151116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN BIOGENETIC SCIENCES INC
- **DATE OF NAME CHANGE:** 19940426

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (date of earliest event reported): February 16, 2023

**<u>QHSLab, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

---

| | |
|:---|:---|
| Nevada | 30-1104301 |
| (State<br> of Incorporation) | (I.R.S. Employer<br> Identification No.) |
| 901 Northpoint Parkway Suite 302 West Palm Beach<br> FL 33407 | 33407 |
| (Address of Principal Executive Offices) | (ZIP Code) |

---

Registrant's telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value** | **USAQ** | **N/A** |

---

**Item 7.01 Regulation FD Disclosure.**

On February 16, 2023, we, QHSLab, Inc. (the "Company"), issued a press release entitled, QHSLab, Inc. Announces representation agreement with Healthcare Information Technology Specialists of Florida. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

By filing this Current Report on Form 8-K and furnishing the information contained herein, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (<u>https://twitter.com/qhslapinc</u>), LinkedIn account (<u>https://www.linkedin.com/company/65407282/admin/</u>), Facebook account (<u>https://www.facebook.com/QHSLabs</u> and Instagram account (<u>https://www.instagram.com/qhslabs/)</u> as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Press Release dated February 16, 2023 QHSLab, Inc. Announces Representation Agreement with Healthcare Information Technology Specialists of Florida.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: February 16, 2023 | Date: February 16, 2023 |
| QHSLab, Inc. | QHSLab, Inc. |
|  | */s/ Troy Grogan* |
| Name: | Troy Grogan |
| Title: | CEO and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![Picture 1](ex99-1_001.jpg)

**QHSLab, Inc. Announces Representation Agreement with Healthcare Information Technology Specialists of Florida**

**WEST PALM BEACH, FL, Feb. 16, 2023 (GLOBE NEWSWIRE)** — QHSLab, Inc. (the "Company") (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, announces entry into a representation agreement with Florida based, Healthcare Information Technology Specialists, LLC.

QHSLab, Inc. (QHSLab) and Healthcare Information Technology Specialists, LLC (HIT) entered into a representation agreement, enabling HIT to recruit its medical office and physician clients to contract with the QHSLab digital healthcare platform. The representation agreement provides commission-based payments to HIT for recruiting its numerous physician and medical practice clients, including onboarding and providing customer service activities related to using the QHS platform.

Tommy Knigge, President at HIT stated, *"We commercially piloted the QHSLab Digital Health Platform in late 2022 with five of our primary care and pediatric service locations. Our initial focus has been related to allergy and asthma care. We and our providers were thrilled with the QHSLab application, and clinical decision-making reports that their digital assessments provide. Additionally, we tested the insurance reimbursement for these services. We were pleasantly surprised with the financial outcomes, so much so that we've begun a broader roll-out to our entire medical practice audience."*

During the successful commercial pilot program, HIT specialists onboarded five medical practice clients. The team at HIT has over 100 similar clients and medical practice relationships and have begun strategic outreach to their audience, introducing the benefits of the QHSLab digital health platform that offers solutions for allergy and asthma, mental health, post COVID condition, preventive care, lifestyle medicine and much more.

 

*"Pioneers like Tommy Knigge are needed today, especially as we advance primary care through digital healthcare solutions. Mr. Knigge's business and medical office experience is invaluable to the ongoing development and methods related to enhancing the patient-provider relationship, optimizing practice workflow, and facilitating seamless integration with today's electronic health records through and with our QHSLab digital medicine programs. Together, we're looking forward to a highly successful 2023,"* said Troy Grogan, President at QHSLab, Inc.

**About Healthcare Information Technology Specialists, LLC**

For the past ten years, Healthcare Information Technology Specialists, LLC have provided electronic health record software solutions, medical billing, allergy and asthma care, and administrative workflow solutions to hundreds of primary care and other medical practices throughout Florida.

**About QHSLab, Inc.**

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.

**Forward-Looking Statements**

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact:**

**Olivia Giamanco**

**QHSLab, Inc.**

**(929) 379-6503**

**<u>ir@usaqcorp.com</u>**

<u>https://twitter.com/USAQcorp</u>